Library
1cP-AL-LAD
1cP-AL-LAD is a novel semisynthetic psychedelic of the lysergamide class. It is structurally related to AL-LAD and is suspected to act as a prodrug for that compound, though this has not been confirmed by formal research. First identified in France in June 2021, it emerged alongside several other novel lysergamides as a designer drug. Very little anecdotal or scientific data is currently available regarding its effects.
Also known as: N1‑cyclopropanoyl AL‑LAD
Classification
- Chemical: Lysergamide
- Psychoactive: Psychedelic
- Tag: Hallucinogen
Effects
- Spontaneous Tactile Sensations
- Stimulation
- Nausea
- Difficulty Urinating
- Spontaneous Bodily Sensations
- Physical Euphoria
- Time Distortion
- Introspection
- Multiple Thought Streams
- Conceptual Thinking
- Ego Suppression Loss And Death
- Thought Loop
- Hallucinations
- Visual Drifting
- Tracers
- After Images
- Symmetrical Texture Repetition
- Color Shifting
Routes of Administration
Oral
Dosage
- Heavy: 350+ ug
- Light: 50 – 100 µg
- Common: 100 – 225 µg
- Strong: 225 – 350 µg
- Threshold: 20 ug
Duration
- Onset: 0.5-1.5 h
- Comeup: 0.5-1 h
- Peak: 2.5-5 h
- Offset: 2-3 h
- After Effects: 2-18 h
- Total Duration: 6.5-10 h
Sublingual
Dosage
- Heavy: 200+ µg
- Light: 15–50 µg
- Common: 50–125 µg
- Strong: 125–200 µg
- Threshold: 15 µg
Duration
- Onset: 0.33-1 h
- Peak: 2-4 h
- Offset: 4.5-7 h
- After Effects: 0.5-6 h
- Total Duration: 6-9 h
Insufflated
Dosage
- Heavy: 150+ µg
- Light: 10–40 µg
- Common: 40–100 µg
- Strong: 100–150 µg
- Threshold: 10 µg
Duration
No data available for this section yet.
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
Links
This static page is intended as a readable non-JS and prerender-friendly library export.